Low- and middle-income countries are carrying the overwhelming share of the world’s cervical cancer deaths, and a new review warns that the survival gap affecting women with gynecologic cancers is being driven less by a lack of scientific knowledge than by failures in prevention, diagnosis, treatment infrastructure, and health-system financing. Published online in the American Cancer Society’s peer-reviewed journal CANCER, the review examines cancers of the cervix, endometrium, ovary, vagina, and vulva and identifies practical interventions that could substantially improve survival if they are incorporated into national cancer-control programs.
The analysis, based on studies published between 2015 and 2024, found that low- and middle-income countries account for approximately 94 percent of global deaths from cervical cancer. The highest mortality was observed in East Africa, where many patients reach medical services only after disease has progressed beyond the stage at which treatment is most effective. Cervical cancer is often preventable because persistent infection with high-risk types of human papillomavirus, or HPV, is its principal cause. Yet prevention technologies, screening services, diagnostic laboratories, surgery, radiotherapy, and systemic treatments remain unevenly available across countries and, in many settings, within the same country.
The survival differences begin long before a patient enters an oncology ward. HPV vaccination can prevent infection with viral types responsible for most cervical cancers, but vaccination coverage is limited in many low-resource settings because of cost, supply constraints, difficult delivery logistics, and insufficient public-health infrastructure. The review highlights single-dose HPV vaccination as one potentially cost-effective and scalable strategy. A simplified schedule could reduce the number of clinic visits and lower delivery costs while making it easier for health systems to reach adolescents in schools, rural communities, and areas where routine immunization programs are incomplete.
For women who were not vaccinated, screening can detect precancerous changes before they become invasive tumors. Traditional cytology-based screening, commonly known as the Pap test, requires trained personnel, laboratory processing, quality control, and systems capable of recalling patients for follow-up. These requirements can be difficult to sustain in under-resourced settings. HPV-based screening directly detects high-risk viral DNA or RNA and can identify women at elevated risk before visible cancer develops. The review points to HPV self-sampling as a particularly promising approach because it can increase privacy, reduce travel barriers, and extend screening to women who might otherwise avoid or be unable to access conventional examinations.
Screen-and-treat programs could further shorten the dangerous interval between diagnosis and therapy. In these models, women who test positive for high-risk HPV may receive an immediate visual assessment and treatment for eligible precancerous lesions, often using ablative methods such as thermal ablation or cryotherapy. The technical advantage is not simply convenience: the approach reduces the risk that patients will be lost between separate testing, diagnostic, and treatment appointments. In health systems where transportation is expensive, clinics are far away, or follow-up records are unreliable, completing the care pathway during a limited number of visits can prevent lesions from progressing into invasive cancer.
Once gynecologic cancer becomes invasive, however, prevention and early detection must be matched by treatment capacity. Radiotherapy is a central component of curative treatment for locally advanced cervical cancer and is also important for selected endometrial, vaginal, and vulvar cancers. External-beam radiotherapy and brachytherapy require expensive machines, reliable electricity, specialized maintenance, radiation-protection systems, treatment-planning software, and trained medical physicists, radiation oncologists, radiographers, and oncology nurses. The review identifies inadequate radiotherapy infrastructure as a major contributor to poor outcomes in low- and middle-income countries, where patients may face long waiting lists, interruptions in treatment, or no local access at all.
Radiotherapy shortages are especially consequential because treatment effectiveness depends on completing therapy within an appropriate overall time. Delays can allow rapidly proliferating tumor cells to repopulate between treatments, potentially reducing the probability of local control. In cervical cancer, radiotherapy is frequently combined with chemotherapy, a strategy known as concurrent chemoradiation, to enhance tumor sensitivity to radiation. When either component is unavailable, unaffordable, or interrupted, the intended biological effect of treatment may not be achieved. Expanding radiotherapy capacity therefore requires more than purchasing machines; it demands long-term investment in infrastructure, quality assurance, supply chains, technical support, and the workforce needed to operate complex services safely.
Workforce shortages affect every stage of care, from vaccination and screening to pathology, surgery, chemotherapy, radiotherapy, palliative medicine, and survivorship services. Many countries have too few gynecologic oncologists, pathologists, radiologists, radiation specialists, and oncology nurses to serve their populations. The authors describe workforce development and international training partnerships as important tools for closing this gap. Sustainable programs may include specialist fellowships, telemedicine, shared clinical protocols, regional referral networks, remote pathology support, and training models that enable local professionals to become educators themselves. Such partnerships are most effective when they strengthen national capacity rather than creating temporary services dependent on visiting teams.
Access to medicines presents another barrier. Patients may be unable to obtain essential chemotherapy, analgesics, blood products, hormonal treatments, targeted therapies, or newer immunotherapies. Novel treatments can offer meaningful benefits for selected patients, but their high prices, regulatory delays, diagnostic requirements, and complex administration can place them beyond the reach of health systems already struggling to provide basic cancer care. The review argues that equitable cancer control must therefore be organized as a system-level effort. Prevention, early diagnosis, surgery, radiation, medicines, palliative care, data collection, and financial protection cannot be treated as isolated projects. They must be coordinated through national policies supported by predictable funding.
“The survival gap in gynecologic cancers between low- and middle-income countries and wealthier nations is not inevitable—it is largely the result of delayed diagnosis and under-resourced health systems,” said corresponding author Alfi Sophian of the Indonesian Food and Drug Authority. He emphasized that proven, cost-effective interventions already exist and that stronger political commitment is needed to embed them in national cancer-control policies. Suresh S. Ramalingam, editor-in-chief of CANCER and executive director of the Winship Cancer Institute of Emory University, said that consistent and uniform implementation of evidence-based tools worldwide could save numerous lives. The review’s central message is direct: closing the gynecologic cancer survival gap will depend not on a single breakthrough, but on making existing breakthroughs reliably available to the women who need them most.
Subject of Research: Gynecologic cancer prevention, diagnosis, treatment, and survival disparities in low- and middle-income countries.
Article Title: “Gynecologic Cancers in Low- and Middle-Income Countries: Bridging the Survival Gap”
News Publication Date: August 24, 2026
Web References: https://doi.org/10.1002/cncr.70518; https://acsjournals.onlinelibrary.wiley.com/journal/10970142; https://newsroom.wiley.com/resources/cancer-news-room/default.aspx
References: Dewi Setiawati, Wachyudi Muchsin, and Alfi Sophian, “Gynecologic Cancers in Low- and Middle-Income Countries: Bridging the Survival Gap,” CANCER, published online August 24, 2026, DOI: 10.1002/cncr.70518.
Keywords: Gynecologic cancer, cervical cancer, HPV vaccination, HPV screening, HPV self-sampling, screen-and-treat, radiotherapy, oncology workforce, health equity, low- and middle-income countries, cancer survival, global health.
Tags: barriers to systemic treatments in low- and middle-income countriescancer control strategies in resource-limited settingscervical cancer screening challengesdisparities in gynecologic cancer diagnosisearly detection and diagnosis of cervical and other gynecologic cancersglobal cervical cancer mortality ratesgynecologic cancer prevention in low-income countrieshealthcare financing for gynecologic cancersHPV vaccination access in middle-income countriesimproving survival rates for womenregional differences in gynecologic cancer outcomestreatment infrastructure gaps in cancer care
